Human adipose-derived pericytes display steroidogenic lineage potential 2 in vitro and influence leydig cell regeneration in vivo in rats by Curley, Michael et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human adipose-derived pericytes display steroidogenic lineage
potential 2 in vitro and influence leydig cell regeneration in vivo
in rats
Citation for published version:
Curley, M, Gonzalez, ZN, Milne, L, Hadoke, P, Handel, I, Peault, B & Smith, L 2019, 'Human adipose-
derived pericytes display steroidogenic lineage potential 2 in vitro and influence leydig cell regeneration in
vivo in rats', Scientific Reports. https://doi.org/10.1038/s41598-019-50855-0
Digital Object Identifier (DOI):
10.1038/s41598-019-50855-0
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Scientific Reports
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 02. Jan. 2020
1Scientific RepoRtS |         (2019) 9:15037  | https://doi.org/10.1038/s41598-019-50855-0
www.nature.com/scientificreports
Human Adipose-derived pericytes 
Display Steroidogenic Lineage 
potential in Vitro and Influence 
Leydig cell Regeneration in Vivo in 
Rats
Michael curley1, Zaniah n. Gonzalez  2, Laura Milne1, patrick Hadoke3, ian Handel4, 
Bruno péault2,5 & Lee B. Smith1,6*
exogenous androgen replacement is used to treat symptoms associated with low testosterone in 
males. However, adverse cardiovascular risk and negative fertility impacts impel development of 
alternative approaches to restore/maintain Leydig cell (Lc) androgen production. Stem Leydig cell (SLc) 
transplantation shows promise in this regard however, practicality of SLc isolation/transplantation 
impede clinical translation. Multipotent human adipose-derived perivascular stem cells (hAd-pScs) 
represent an attractive extragonadal stem cell source for regenerative therapies in the testis but their 
therapeutic potential in this context is unexplored. We asked whether hAd-pScs could be converted 
into Leydig-like cells and determined their capacity to promote regeneration in Lc-ablated rat testes. 
Exposure of hAd-PSCs to differentiation-inducing factors in vitro upregulated steroidogenic genes but 
did not fully induce LC differentiation. In vivo, no difference in LC-regeneration was noted between 
Sham and hAd-pSc-transplanted rats. interestingly, Cyp17a1 expression increased in hAd-pSc-
transplanted testes compared to intact vehicle controls and the luteinising hormone/testosterone 
ratio returned to Vehicle control levels which was not the case in eDS + Sham animals. notably, hAd-
PSCs were undetectable one-month after transplantation suggesting this effect is likely mediated 
via paracrine mechanisms during the initial stages of regeneration; either directly by interacting with 
regenerating Lcs, or through indirect interactions with trophic macrophages.
Establishment and maintenance of the male phenotype requires adequate production and action of androgens 
(e.g. testosterone) which are primarily produced by Leydig cells located in the testicular interstitium. Further to 
their well-established role in male reproductive development and function, increasing evidence suggests andro-
gens also support overall general health in men as low circulating testosterone levels are associated with chronic 
cardio-metabolic disorders1–5. Androgen replacement therapy is commonly used to treat symptoms associated 
with lower circulating testosterone both in ageing men with late-onset hypogonadism and in young hypogo-
nadal males. However, exogenous testosterone replacement disrupts the hypothalamic-pituitary-gonadal (HPG) 
axis compromising fertility6,7 - a potentially catastrophic side effect for younger men wishing to father children. 
Moreover, the risks and benefits of androgen replacement therapy, particularly in older men, are unclear with 
a number of clinical studies reporting adverse cardiovascular events associated with exogenous testosterone 
administration8–10. As such, novel therapies which promote and/or maintain endogenous HPG axis function, 
1MRC Centre for Reproductive Health, University of Edinburgh, The Queen’s Medical Research Institute, 47 Little France 
Crescent, Edinburgh, EH16 4TJ, United Kingdom. 2MRC Centre for Regenerative Medicine, University of Edinburgh, 
Edinburgh Bioquarter, 5 Little France Drive, Edinburgh, EH16 4UU, United Kingdom. 3The British Heart Foundation 
Centre for Cardiovascular Science, University of Edinburgh, The Queen’s Medical Research Institute, Edinburgh, EH16 
4TJ, United Kingdom. 4The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, 
Edinburgh, EH25 9RG, United Kingdom. 5Department of Orthopaedic Surgery and Broad Stem Cell Center, University 
of California at Los Angeles, 615 Charles E Young Dr S, Los Angeles, CA, 90095, USA. 6School of Environmental and Life 
Sciences, University of Newcastle, Callaghan, NSW, 2308, Australia. *email: lee.smith@ed.ac.uk
open
2Scientific RepoRtS |         (2019) 9:15037  | https://doi.org/10.1038/s41598-019-50855-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
keeping testicular testosterone production within a normal physiological range, may be more appropriate to 
improve Leydig cell function in cases of primary hypogonadism. Ideally, a single long-lasting therapeutic inter-
vention would likely be more cost-effective compared to repeated exogenous testosterone replacement however, 
overcoming time and cost associated with initial steps of in vitro expansion/manipulation of stem cells popula-
tions remain a significant challenge.
The identity and behaviour of the stem cells that give rise to testosterone-producing Leydig cells within the 
testicular interstitium has been an area of intense research - particularly in relation to harnessing their regener-
ative properties as an alternative to exogenous androgen replacement. Stem Leydig cells have been prospectively 
isolated from rodent and human testes and extensively characterised both in vitro and in in vivo transplantation 
models11–14. Although these studies have significantly enhanced our understanding of stem Leydig cell differen-
tiation, extraction of stem cells from a patient’s testis may be impractical – potentially limiting their utility as a 
regenerative cell therapy. As such, identification of a suitable extra-gonadal stem cell source is required. Whilst 
the precise origin of stem Leydig cells within the testis is debated, with both peritubular15 and perivascular16 
origins proposed; Davidoff et al. suggested that, following EDS-mediated Leydig cell ablation in rats, Leydig cells 
regenerate from perivascular stem cells (PSCs) which express neural/glial antigen 2 (NG2) and platelet-derived 
growth factor receptor-beta (PDGFRβ)16. Interestingly, a universal identity for multipotent stem cells residing in 
the perivascular niche in multiple tissues has been proposed. Specifically, PSCs are identifiable by NG2, PDGFRβ 
and CD146 (cluster of differentiation 146) expression and they also express as a number of ‘mesenchymal stem 
cell’ markers including CD9017. These markers also identify stem Leydig cells in the testis12,16,18, raising the pos-
sibility that extra-gonadal PSCs may represent a viable option for use in autologous regenerative cell therapies to 
promote Leydig cell function.
Adipose tissue is a well-endowed source of PSCs and is easily accessible with minimally invasive techniques. 
Mouse adipose-derived stem cells have been driven down the steroidogenic lineage in vitro following transduc-
tion with a steroidogenic factor-1 (SF1) expressing adenovirus19. However, the resulting cells favourably produced 
glucocorticoids over androgens suggesting additional factors are required to obtain functional Leydig-like cells. 
In an experimentally induced ageing model, intravenous injection of rat adipose-derived stem cells were reported 
to alleviate testicular dysfunction although the mechanism is unclear20. The regenerative properties of human 
adipose-derived perivascular stem cells (hAd-PSCs; CD146pos, CD34neg, CD31neg, CD45neg), acting via direct and 
paracrine mechanisms, have been recognised in orthopaedic research models21–24. However, the regenerative 
potential of hAd-PSCs to promote Leydig cell function in the testis has not been explored. Specifically, whether 
hAd-PSCs can be transformed into Leydig-like cells in vitro and/or in vivo and if they can support endogenous 
Leydig cell regeneration/function is unknown.
To address this, we exposed hAd-PSC cultures to a predefined combination of hormones and growth factors 
known to induce in vitro differentiation of human and rodent stem Leydig cells. Additionally, we transplanted 
hAd-PSCs cultured with or without differentiation inducing factors into Leydig cell-ablated rat testes and mon-
itored Leydig cell regeneration over 35 days. This revealed that whilst hAd-PSCs may harbour some steroido-
genic lineage potential in vitro, they do not directly contribute to the regenerating Leydig cell population in vivo. 
Instead, hAd-PSCs may promote endogenous Leydig cell regeneration and increase the size of the newly formed 
Leydig cell population.
Results
Steroidogenic potential of hAd-pScs in vitro. Human adipose-derived perivascular stem cells are 
multipotent stem/progenitor cells with myogenic, osteogenic and adipogenic properties21,22,25,26. However, the 
steroidogenic potential of hAd-PSCs has not been reported. Therefore, we first asked whether hAd-PSCs could 
be transformed into steroidogenic Leydig-like cells in vitro. hAd-PSCs were cultured in a differentiation inducing 
media (DIM) containing luteinising hormone (LH), platelet-derived growth factor beta (PDGF-BB), insulin-like 
growth factor-1 (IGF-1) and thyroid hormone (T3). This combination of trophic factors can stimulate differenti-
ation of rodent and human stem Leydig cells in vitro11–14. As such, we reasoned it could induce the steroidogenic 
lineage in extra-gonadal hAd-PSCs. After one week of culture, cells were harvested and the mRNA expression of 
genes involved in androgen biosynthesis was measured by qRT-PCR and compared to control cells cultured in 
expansion media only (EM; DMEM GlutaMAX™/fetal bovine serum). Exposure of hAd-PSCs to DIM induced 
the expression of STAR and CYP11A1 (Fig. 1), encoding the steroidogenic acute regulatory protein and P450 
cholesterol side-chain cleavage enzyme which function in the initial and rate-limiting steps of steroidogenesis. 
Conversely, neither CYP17A1 nor HSD17B3, encoding the enzymes 17α-hydroxylase, 17,20-lyase and hydrox-
ysteroid dehydrogenase 17-beta type 3 required for the final steps of the classical androgen biosynthetic pathway, 
were detected in EM or DIM cultured hAd-PSCs (Fig. 1). These data suggest that, whilst hAd-PSCs can be driven 
to differentiate towards a steroidogenic lineage, these specific in vitro conditions are insufficient to convert them 
into fully functional Leydig-like cells.
hAd-pScs are not incorporated into the newly formed Leydig cell population in Vivo. The 
full complement of factors that control adult Leydig cell development in vivo is yet to be defined. As such, deri-
vation of functional Leydig-like cells from hAd-PSCs likely requires additional critical mediators of Leydig cell 
development. To determine whether unknown trophic factors could complete the transformation of hAd-PSCs 
to Leydig-like cells, we transplanted either EM or DIM cultured hAd-PSCs into the interstitial compartment 
of the rat testis 4 days after EDS-mediated Leydig cell ablation (i.e. into a bona fide environment conducive to 
Leydig cell development). When animals were sacrificed 35 days after EDS treatment, no difference in body 
weight was observed between groups, suggesting neither EDS nor hAd-PSCs had major negative systemic 
side effects (Supplemental Fig. 1). Recovery of testis weight to that of Vehicle + Sham controls was observed 
in the EDS + Sham and EDS + hAd-PSC (DIM) groups. Although there was no significant difference in testis 
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weight between any of the EDS-treated groups, EDS + Ad-PSC (EM) testes remained significantly lighter than 
Vehicle + Sham controls at 35 days post EDS which may represent delayed recovery of spermatogenesis following 
transient androgen deprivation in this group (Fig. 2A).
Testicular histology was grossly similar between groups at 35 days post EDS, with complete spermatogen-
esis taking place within seminiferous tubules, and abundant interstitial Leydig cells (Fig. 2B). However, in 
EDS + hAd-PSC (EM) and EDS + hAd-PSC (DIM) groups, occasional regions containing atrophic seminiferous 
tubules were observed (Supplemental Fig. 2). As this was not observed in the EDS + Sham control group, it may 
be a consequence of an immune response to the xenogenic hAd-PSCs rather than a due to surgical procedures 
or EDS toxicity. When genomic DNA (gDNA) was isolated from control and hAd-PSC transplanted testes and 
interrogated for the presence of human-specific gDNA (HUMSAT17A), no human gDNA was detected either in 
EM or in DIM hAd-PSC transplanted testes (Fig. 2C). While we cannot rule out a transient transformation of 
hAd-PSCs into Leydig-like cells at earlier time-points, these data suggest that they are not incorporated into, and 
retained within, the endogenous Leydig cell population in this xenogeneic transplantation model.
Effect of hAD-PSCs on Endogenous Leydig cell Regeneration and Function in vivo. Complete 
Leydig cell ablation occurs within 3–7 days following EDS administration, followed by regeneration of the endog-
enous Leydig cell population and restoration of circulating testosterone levels within 3–6 weeks27,28. To monitor 
Leydig cell development in control and hAD-PSC transplanted testes, serial measurement of circulating testos-
terone (T) and luteinising hormone (LH) concentrations was performed (Fig. 3A). Testosterone was undetectable 
7 days after EDS treatment but returned to control levels by 21 days (Fig. 3B), confirming successful Leydig cell 
ablation and regeneration. To determine the impact of the transplanted hAd-PSCs on recovery of circulating 
testosterone between these time points, area under the curve (AUC) was calculated. As expected, AUC was sig-
nificantly decreased in all EDS treated groups compared to Vehicle + Sham controls. However, no difference was 
observed when EM or DIM cultured hAd-PSCs were transplanted into the testis (Fig. 3B). In line with the circu-
lating testosterone profile, an increase in LH, peaking at 14 days, was observed following EDS treatment (Fig. 3C). 
AUC analysis (0–21 days post EDS) revealed that the LH spike, induced by removal of testosterone negative 
Figure 1. Induction of steroidogenic mRNA expression in hAd-PSCs cultured in differentiation inducing 
medium. Expression of STAR (steroidogenic acute regulatory protein) and CYP11A1 (P450 cholesterol 
side-chain cleavage enzyme) was induced in human adipose-derived perivascular stem cells (hAd-PSCs) 
after one week culture in differentiation inducing media (DIM; t-test; ****p =  < 0.0001). Neither CYP17A1 
(17α-hydroxylase, 17,20-lyase) nor HSD17B3 (hydroxysteroid dehydrogenase 17-beta type 3) were detectable. 
Arrows in bottom panels indicate the amplification adult human testis cDNA as a positive control. Data 
presented are mean ± SEM from n = 6 separate wells per group. N.D = Not detected.
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feedback following Leydig cell ablation, was significantly blunted in the hAd-PSC (DIM) group compared to the 
hAd-PSC (EM) group (Fig. 3C) although not significantly different from EDS + Sham controls.
We next asked whether Leydig cell number and/or function was altered in testes transplanted with either 
EM or DIM cultured hAd-PSCs. When assessed 35 days after EDS-mediated Leydig cell ablation, positive 
immunostaining for the Leydig cell marker hydroxysteroid dehydrogenase 3-beta (HSD3B) was observed in 
the interstitial compartment of Vehicle + Sham and EDS + Sham control testes as expected. Positive HSD3B 
staining was also observed both in EM and in DIM hAd-PSC transplanted testes (Fig. 4A). Surprisingly, ste-
reological analysis revealed a significant increase in the number of Leydig cells in hAd-PSC (DIM) testes com-
pared to Vehicle + Sham controls (Fig. 4B). Although we noted no significant differences between hAd-PSC 
and EDS + sham groups, Leydig cell numbers in EDS + Sham and EDS + hAd-PSC (EM) were not significantly 
increased compared to Vehicle + Sham Controls. Circulating testosterone relative to Leydig cell number was 
reduced in EDS + Sham and both hAd-PSC (EM) and (DIM) transplanted groups (Fig. 4C). However, seminal 
vesicle weight (as a readout of peripheral androgen action29–31) recovered to the equivalent of Vehicle + Sham 
controls only in the hAd-PSC (DIM) group although no differences were noted between EDS + Sham and 
hAd-PSC-transplanted groups. Additionally, the LH/T ratio (as an indicator of primary Leydig cell function) 
remained significantly elevated in the EDS + Sham group, whereas no difference was noted between EM or DIM 
hAd-PSC and Vehicle + Sham control groups (Fig. 4E). This suggests that the function of the newly formed 
Figure 2. Effect of hAd-PSCs on testis weight and histology. (A) Testis weight recovered to Vehicle + Sham 
control values in EDS + Sham and EDS + hAd-PSC (DIM) groups but remained significantly lower in the 
EDS + hAd-PSC (EM) group (Kruskal-Wallis; p = 0.0264). Means were compared between groups using Dunn’s 
post hoc analysis. Groups that share a letter superscript are not significantly different. Data presented are 
mean ± SEM from n = 5–6 animals per group. (B) Representative H&E stained testis sections revealed testicular 
architecture was largely normal 35 days post Leydig cell ablation. Full spermatogenesis within seminiferous 
tubules (ST) and abundant interstitial Leydig cells (arrows) were observed in all groups. Scale = 100 µm. (C) 
Multiplex genomic PCR for human and rat specific genomic DNA (HUMSAT17A; 450 bp and Actb; 552 bp 
respectively) in testis biopsies 35 days after transplantation (EDS + 35). No human DNA was detected in either 
hAd-PSC (EM) or hAd-PSC (DIM) transplanted testes. Genomic DNA isolated directly from EM and DIM 
hAd-PSC cultures was included as a positive control.
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Leydig cell population may be improved when hAd-PSCs are transplanted into the testis interstitium following 
EDS-mediated Leydig cell ablation. To further probe Leydig cell function, we measured mRNA expression levels 
of luteinising hormone/chorionic gonadotrophin receptor (Lhcgr) and steroidogenic acute regulatory protein 
(Star) as well as cytochrome P450 and hydroxysteroid dehydrogenase enzymes required for the conversion of 
cholesterol to testosterone in Leydig cells (Cyp11a1, Cyp17a1 and Hsd3b1, Hsd17b3 respectively). No difference in 
the expression of Lhcgr, Star, Cyp11a1, Hsd3b1 or Hsd17b3 was noted between control and hAd-PSC transplanted 
testes. However, a significant increase in Cyp17a1 expression (required for the conversion progestagens to andro-
gens) was observed both in (EM) and in (DIM) hAd-PSC transplanted testes (Fig. 5). This pattern of expression 
was similar when data were corrected for Leydig cell number (Supplemental Fig. 3) and therefore reflects an 
alteration in Leydig cell function, rather than simply resulting from an increase in Leydig cell number. Together, 
Figure 3. Circulating hormone measurements following Leydig cell ablation and hAd-PSC transplantation. 
(A) Leydig cells were ablated using a single dose of ethane dimethanesulphonate (EDS). Human perivascular 
stem cells (hAd-PSCs), cultured in expansion medium (EM) or differentiation inducing medium (DIM), 
were transplanted into the testis interstitium 4 days after EDS. Circulating hormones were measured in sera 
from tail vein bleeds collected weekly until animals were sacrificed after 35 days (EDS + 35). Both individual 
animals (i) and the mean ± SEM for each group (ii) are plotted. Circulating testosterone (B) was undetectable 
in EDS-treated animals after 7 days and returned to Vehicle + Sham control levels after 21 days. Area under 
the curve (AUC) analysis (Biii) revealed no difference in recovery of circulating testosterone levels in animals 
transplanted with either EM or DIM treated hAd-PSCs compared to EDS + Sham controls. Circulating 
luteinising hormone (C) increased following EDS administration, peaking at 14 days, and returned to 
Vehicle + Sham control levels after 28 days. AUC (Ciii) was significantly lower in the hAd-PSC (DIM) group 
compared to the hAd-PSC (EM) group. 1-way ANOVAs were used to identify differences between groups 
(p =  < 0.0001 for both testosterone and LH). Tukey’s post-hoc analysis was used to compare means between 
groups where a shared letter denotes no significant difference. The orange shaded areas in (ii) highlight the 
proportion of the data used for area under the curve (AUC, iii) analyses based on the time taken for testosterone 
to return to Vehicle + Sham control levels in EDS + Sham animals (EDS + 21). Data presented are mean ± SEM 
from n = 5–6 separate animals per group.
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these data indicate that hAd-PSCs pre-exposed to differentiating-inducing factors may promote primary function 
and, intriguingly, the final size of the regenerating Leydig cell population.
Discussion
The current strategy for treating hypogonadism is the administration of exogenous testosterone. However, this 
approach can have negative side effects including adverse cardiovascular events8–10 and disruption of normal 
spermatogenesis which may not be desirable if maintenance of fertility is required6,7. In recent years, efforts have 
been focussed on developing stem cell-based regenerative therapies to restore endogenous androgen production 
as an alternative to exogenous testosterone replacement32. Ultimately, a single, long-lasting therapeutic inter-
vention could prove more cost-effective than repeated testosterone replacement. In the current study, we asked 
whether human adipose-derived perivascular stem cells (hAd-PSC) could be converted into testosterone produc-
ing Leydig-like cells. We also assessed the regenerative capacity of hAd-PSCs to promote endogenous testosterone 
production in an in vivo rat model of Leydig cell ablation-regeneration. Our results demonstrate that hAd-PSCs 
harbour some steroidogenic lineage potential in vitro but they do not directly contribute to the regenerating 
Leydig cell population in vivo. Instead, hAd-PSCs may influence endogenous Leydig cell regeneration, increasing 
the size of the newly formed Leydig cell population perhaps via paracrine mechanisms during the initial stages of 
regeneration. However, whether autologous hAd-PSCs could be isolated and directly transplanted back into the 
testis, bypassing the time and cost of in vitro expansion and/or differentiation, remains to be tested.
In 2006, Ge and colleagues described a cocktail of hormones and growth factors sufficient for the in vitro gen-
eration of testosterone-producing Leydig-like cells from platelet derived growth factor alpha-positive (PDFGR-α) 
stem cells isolated from neonatal rat testes. More recently, this differentiation inducing media (DIM) has been 
used to generate testosterone producing Leydig-like cells both from nestin-positive and CD51-positive stem cell 
Figure 4. Effect of hAd-PSCs on Leydig cell number and function. (A) Immunostaining of hydroxysteroid 
dehydrogenase 3-beta (HSD3B) marking testicular Leydig cells 35 days after ethane dimethanesulphonate 
(EDS)-mediated Leydig cell ablation with or without transplantation of hAd-PSCs cultivated in either 
expansion medium (EM) or differentiation inducing medium (DIM). Inset = primary antibody negative 
control. Scale bars = 100 µm. (B) Stereological analysis revealed a significantly increased number of Leydig 
cells in testes transplanted with hAd-PSCs (DIM) compared to Vehicle + Sham controls (1-way ANOVA; 
p = 0.0204). (C) Circulating testosterone relative to Leydig cell number was reduced in all three experimental 
groups compared to Vehicle + Sham controls (1-way ANOVA; p = 0.0035). However, seminal vesicle weight 
(D) as a marker of peripheral androgen action was recovered to Vehicle + Sham control levels in the hAd-
PSC (DIM) group (1-way ANOVA; p = 0.0044). (E) The luteinising hormone:testosterone ratio remained 
significantly elevated in the EDS + Sham group but not in either hAd-PSC transplanted group compared to 
Vehicle + Sham controls (Kruskal-Wallis; p = 0.0083). For one-way ANOVA, means were compared between 
groups using Tukey’s post hoc analysis. For Kruskal-Wallis, means were compared between groups using 
Dunn’s post hoc analysis. In each case, groups that share a letter superscript are not significantly different. Data 
presented are mean ± SEM from n = 5–6 animals per group.
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populations isolated from neonatal and adult mouse testes respectively12,13. In each of these studies, induction of 
steroidogenic cell lineage markers including SF-1, GATA-4, LHCGR, STAR, CYP11A1, HSD3B6 and CYP17A1 
was reported after 7–11 days of culture in DIM. Whilst none of the above studies demonstrated the expression 
of HSD17B3 – the enzyme required for the final step of classical testosterone biosynthesis – all reported testos-
terone production by cells cultured in DIM, suggesting a successful transformation of the respective stem cell 
populations into functional Leydig-like cells. In the present study, we were able to detect the expression of STAR 
and CYP11A1 in cultures of hAd-PSCs exposed to DIM for 7 days however, neither CYP17A1 nor HSD17B3 were 
detectable. As such, whilst hAd-PSCs exposed to DIM may acquire some steroidogenic potential, these specific 
in vitro conditions are not sufficient to convert them into functional testosterone producing cells. This could 
be attributed to divergent responsiveness of rodent and human stem cells to DIM. However, Leydig-like cells 
have been generated from human p75-positive testicular stem cells following DIM exposure; albeit after a longer 
incubation of 28 days14. As such, it is likely that additional experimental factors may preclude complete trans-
formation of hAd-PSCs into functional Leydig-like cells. For example, the expansion media utilised in previous 
studies contained additional supplements including dexamethasone, leukemia inhibitory factor, platelet derived 
growth factor-beta, fibroblast growth factor and epidermal growth factor11–14. These factors have been implicated 
in aspects of Leydig cell development and function28,33–40 and thus, may ‘prime’ the cells for steroidogenic lineage 
differentiation prior to DIM exposure. Additionally, significant heterogeneity exists between stem cells isolated 
from different tissues, or even between stem cell sub-populations isolated from the same tissue26,41–44. Therefore, 
whilst hAd-PSCs possess multi-lineage potential25, stem cell subsets isolated from testis tissue may have increased 
propensity to develop into Leydig cells. This requires further investigation. Interestingly, we observed CYP11A1 
Figure 5. Leydig cell steroidogenic mRNA expression. No difference in mRNA expression levels of luteinising 
hormone/chorionic gonadotropin receptor (Lhcgr); steroidogenic acute regulatory protein (Star); P450 
cholesterol side-chain cleavage enzyme (Cyp11a1); hydroxysteroid dehydrogenase 3-beta (Hsd3b); or 
hydroxysteroid dehydrogenase 17-beta type 3 (Hsd17b3) was noted between experimental groups and 
Vehicle + Sham controls (1-way ANOVA). However, expression of 17α-hydroxylase, 17,20-lyase (Cyp17a1) was 
significantly increased both in hAd-PSC (EM) and in hAd-PSC (DIM) groups (1-way ANOVA; p = 0.0025). 
Tukey’s post-hoc analysis was used to compare means between groups. Groups that share a letter superscript are 
not significantly different. Data presented are mean ± SEM from n = 5–6 separate animals per group.
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expression in hAd-PSCs cultured in EM only, albeit at a lower level than DIM-cultured cells. At present, we 
cannot conclude whether EM specifically induces the expression of CYP11A1 in hAd-PSCs or if endogenous 
hAd-PSCs express CYP11A1 prior to isolation and culture. The extent to which stem cell-like behaviours of peri-
cytes, or indeed other ‘stem cells’ are an artefact of ex vivo and in vitro manipulations is not entirely clear. Thus, we 
use the term ‘stem cell’ with caution45. Recently, it has been suggested that, in adult mice, endogenous pericytes in 
multiple organs do not behave as stem cells in vivo46. Therefore, hAd-PSCs may only possess limited stem cell-like 
properties rather than being true ‘stem cells’ capable of Leydig cell differentiation.
Testicular development and function is tightly regulated by a complex paracrine signalling network and the 
full complement of factors that control adult Leydig cell development in vivo is yet to be defined. Furthermore, 
the majority of our understanding comes from rodent models and thus, we may underappreciate the require-
ments for human adult Leydig cell development. Nevertheless, we reasoned that transplantation into the rat tes-
tis interstitium during Leydig cell regeneration (following EDS-mediated Leydig cell ablation) would expose 
hAd-PSCs to additional trophic factors and possibly promote differentiation into Leydig-like cells. In general, no 
differences in Leydig cell regeneration were noted between Sham and hAd-PSC-transplanted groups following 
EDS exposure. Neither EM nor DIM cultured hAd-PSCs appeared to affect the eventual recovery of circulating 
testosterone levels and transplanted hAd-PSCs were not incorporated into the regenerating Leydig cell popula-
tion. Previous studies have demonstrated that the size newly regenerated Leydig cell population following EDS 
treatment is equal to intact Vehicle controls 5-weeks post EDS injection in Wistar rats47. In the present studies, 
transplantation of DIM cultured hAd-PSCs increased endogenous Leydig cell number above Vehicle + Sham 
animals and, seminal vesicle weight (as a measure of peripheral androgen action) was recovered equivalent to 
Vehicle + Sham controls which was not observed either in EDS + Sham or in EDS + hAd-PSC (EM) animals. 
Furthermore, in hAd-PSC transplanted animals, Cyp17a1 expression (required for the conversion of progestagens 
to androgens) was increased following EDS exposure compared to Vehicle + Sham controls and the luteinising 
hormone/testosterone ratio (as a measure of primary Leydig cell function) returned to Vehicle + Sham control 
levels. In each case, this was not observed in EDS + Sham animals and may be a subtle indicator of altered Leydig 
cell regeneration kinetics in hAd-PSC-transplanted testes. Whether this is a direct attribute of hAd-PSCs or is 
simply an adjuvant-type response in the testicular microenvironment requires further investigation. Interestingly, 
accelerated adult Leydig cell development and increased Cyp17a1 expression has been described in fetal Leydig 
cell-ablated rat testes48. Additionally, injection of FGF16 into the rat testis interstitium following Leydig cell abla-
tion stimulates stem and immature Leydig cell proliferation resulting expansion of the adult Leydig cell pop-
ulation49. These studies highlight a role for the interstitial microenvironment in controlling adult Leydig cell 
development/number and support our hypothesis that alterations in the testis microenvironment induced by 
hAd-PSCs may influence Leydig cell population size. It is noteworthy that testicular macrophages are intimately 
involved in Leydig cell development and function50–52. Following EDS treatment, testicular macrophages are acti-
vated to clear apoptotic Leydig cells from the interstitium53,54 and it has been previously documented that testic-
ular macrophages influence Leydig cell response to pituitary gonadotrophin51,55. As such, enhanced macrophage 
activation following introduction of xenogenic hAd-PSCs into Leydig cell-ablated testes may explain the changes 
in Leydig cell number/function observed in hAd-PSC-transplanted rats. This requires further investigation.
A number of studies have reported successful engraftment and differentiation of rodent stem Leydig cells 
following EDS mediated Leydig cell ablation in immunocompetent hosts11–13. However, in these studies testes 
were analysed 10–12 days after transplantation. Therefore, whether the cells could survive longer term engraft-
ment is unclear. In the current study, we were unable to detect hAd-PSCs in transplanted testes 1 month after 
injection, indicating that they do not survive long term in the rat testis. This is consistent with previous reports of 
hAd-PSCs in a mouse model of ischaemic heart injury56. Lineage tracing of GFP labelled hAd-PSCs transplanted 
into the myocardium demonstrated that only a very small number of cells differentiated into cardiac cells; sug-
gesting the positive effects of hAd-PSCs on cardiac recovery were likely mediated by a paracrine mecahnism56. 
Similarly, adipose-derived stem cells were reported to have positive effects in a rat model of tobacco-induced 
erectile dysfunction by reducing oxidative stress. EdU (5-ethynyl-2′-deoxyuridine) labelling of transplanted cells 
revealed minimal engraftment four weeks after injection leading the authors to speculate that paracrine release of 
cytokines/growth factors may be responsible for the therapeutic effect57. Indeed, perivascular stem cells secrete a 
variety of factors including PDGF-BB58 and leukemia inhibitory factor (LIF)56, both of which are thought to play 
a role in stem Leydig cell proliferation/differentiation28,38. Furthermore, pre-incubation of primary rat Leydig cells 
with PDGF-BB significantly enhances LH-stimulated testosterone synthesis59.
Previous studies have demonstrated that macrophage number increases 2–3 fold to clear apoptotic Leydig cells 
following EDS treatment54,55 and, when testicular macrophages are depleted, Leydig cells do not fully regenerate52 
highlighting an important role of trophic macrophages in the Leydig cell regeneration process. Additionally, 
increasing macrophage number in the testis has been shown to reduce LH levels without changing testosterone 
levels suggesting a systemic as well as local effect of macrophages on Leydig cell function. It is therefore conceiva-
ble that transplantation of xenogenic hAd-PSCs into the rat testis may have enhanced the ongoing inflammatory 
process in the EDS-exposed testes and thus impact the initial stages of Leydig cell regeneration. We did notice foci 
containing atrophic seminiferous tubules in hAd-PSC-transplanted testes 35-days after EDS-mediated Leydig 
cell ablation which may be indicative of an aberrant inflammatory response to xenogenic hAd-PSCs as this was 
not observed in EDS + Sham testes. However, as we sacrificed animals only at 35-days post EDS, we could not 
fully evaluate this possibility. As such, the full extent to which hAd-PSCs influence Leydig cell regeneration and 
identification of the precise mechanisms (direct or indirect) by which they influence Leydig cell population size 
requires further study.
We acknowledge that our studies used a relatively small number of immunocompetent animals without 
immunosuppression, which may have enhanced the inflammatory response to Leydig cell death post EDS treat-
ment due to xenogeneic rejection. However, previous studies of xenogenic transplantation in immuno-deficient 
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models also noted limited survival and differentiation of transplanted stem cells, despite positive effects on tissue 
regeneration56,60,61. Additionally, the hAd-PSCs used in this study were derived from a single donor which may 
confound our assessment of the regenerative capacity of hAd-PSCs as donor age and sex may influence hAd-PSC 
activity62. Nevertheless, these studies are, to the best of our knowledge, the first description of human Ad-PSCs in 
an in vivo model of Leydig cell injury. We suggest that transplantation of DIM-exposed hAd-PSCs into the Leydig 
cell-ablated testis increases the final size of the regenerated Leydig cell population above intact Vehicle + Sham 
controls, but not EDS + Sham animals, likely via paracrine interactions during the initial stages of regeneration. 
Whether this is a direct effect on Leydig stem/progenitors, or indirectly via activation of testicular macrophages 
requires further investigation.
Materials and Methods
ethics. Animal experimentation was carried out in compliance with the Animals (Scientific Procedures) Act, 
1986. All procedures were approved by University of Edinburgh Animal Welfare and Ethical Review Body and 
were conducted with licenced permission under UK Home Office regulations (project licence number 70/8804 
held by Professor Lee B. Smith). Permission for the collection of tissue and subsequent research was granted in 
Edinburgh by the South East Scotland Research Ethics Committee (Reference: 10/S1103/45).
Animals. Animals were maintained on a 12 hr light cycle (07:00–19:00) with controlled temperature (20–
25 °C) and humidity (~55%). Soya-free chow and drinking water were available ad libitum. Male Wistar Kyoto 
rats (Wky/NCrl; n = 24) at 70–90 days of age were obtained from Charles River (Charles River Laboratories, 
Margate, UK). The animals were housed in groups of 4. Animals were acclimatised for at least one week prior to 
entry into experiments. The experimental overview is outlined in Fig. 2A.
Leydig cell ablation. To ablate testicular Leydig cells, rats were treated with the alkylating agent ethane 
dimethanesulphonate (EDS), which has been widely used to induce Leydig cell-specific ablation and regenera-
tion27,63. The EDS used in this study was a kind gift from Professor Peter O’Shaughnessy (Institute of Biodiversity, 
Animal Health and Comparative Medicine, University of Glasgow). On the day of injection, EDS was dissolved in 
sterile dimethyl sulfoxide DMSO (Hybri-Max™; Sigma-Aldrich, Dorset, UK) at 200 mg/mL. Immediately prior 
to injection, a 50 mg/mL working solution was prepared by diluting into DMSO:Water (1:3). Animals were dosed 
with 85 mg/kg EDS via intraperitoneal injection. Control animals were injected with an equivalent volume of 
vehicle (DMSO:Water).
hAd-pSc culture and transplantation. Human adipose-derived perivascular stem cells (hAd-PSCs; 
CD146pos, CD34neg, CD31neg, CD45neg) used in these studies were isolated from the stromal vascular fraction 
of human lipoaspirates as previously described25. hAd-PSCs were maintained in expansion media (EM) con-
sisting of DMEM GlutaMAX™ (Thermo Scientific, UK) supplemented with 20% (vol/vol) fetal bovine serum 
(FBS; Thermo Scientific, UK) and 1% (vol/vol) penicillin-streptomycin (Thermo Scientific, UK), at 37 °C with 5% 
CO2. One week prior to transplantation, sub-confluent cultures were either switched to a previously described 
differentiation-inducing media (DIM11), or maintained in EM. DIM consisted of phenol red-free DMEM/F-12 
supplemented with 2% FBS, 1% penicillin-streptomycin (each from Thermo Scientific, UK), 10 ng/mL recom-
binant human platelet-derived growth factor beta (rhPDGF-BB), 1 ng/mL human luteinising hormone (hLH), 
70 ng/mL recombinant human insulin-like growth factor-1 (rhIGF-1), 1 nM 3,3′,5-Triiodo-L-thyronine sodium 
salt (thyroid hormone, T3; UK) and 1X human ITS supplement (each from Sigma-Aldrich, UK). Cells were 
transplanted into the testis interstitium 4 days after EDS-mediated Leydig cell ablation. Briefly, testes were 
exposed, through a scrotal incision, under isoflurane anaesthesia. On average, approximately 1.8 (±0.62) mil-
lion cells in 50 µL Opti-MEM™ (Thermo Scientific, UK) were injected under the tunica albuginea using a 
Micro-Fine™ + 0.3 mL (30 G) syringe (BD Bioscience, UK). A single sub-cutaneous injection of analgesic 
(Buprenorphine; 0.05 mg/kg) was administered prior to the animals regaining consciousness. A sham operation 
(injection of 50 µL of Opti-MEM™ only) was carried out on control animals.
tissue collection and processing. Blood samples were collected from the tail vein weekly between 08:00 
and 11:00am for the duration of the experiment (5 weeks in total). Approximately 500 µL blood was collected into 
EDTA coated tubes (Greiner Bio-One, UK) and centrifuged at 1400 g for 10 mins to separate serum. Sera were 
stored at −80 °C. At the end of the experiment (35 days post EDS administration), body, testis and seminal vesicle 
weights were recorded. One testis from each animal was fixed in Bouin’s solution for 8 hrs. After fixation, testes 
were processed, embedded in paraffin wax and 5 µm sections prepared for histological analyses. The contralateral 
testis was frozen on dry ice and stored at −80 °C.
Histological and immunohistochemistry. For general histological analysis, testis sections were stained 
with Haematoxylin and Eosin (H&E) following standard protocols. Immuno-labelling of Leydig cells was 
achieved by a chromogenic immunostaining procedure. Briefly, tissue sections were dewaxed and rehydrated 
following standard procedures. Heat-induced epitope retrieval was carried out by boiling tissue sections in 
0.01 M citrate buffer (pH 6.0) using a Decloaking Chamber™ Pro (Biocare Medical, USA). Endogenous perox-
idase activity was quenched by immersion of sections in 0.3% (v/v) hydrogen peroxide in Tris-buffered saline 
(TBS; pH 7.4) for 30 mins at room temperature. All incubations were carried out in a humidity chamber. Sections 
were subjected to 3 × 5 min washes in TBS between each incubation step. Binding of antibodies to non-specific 
epitopes was blocked by incubating sections with a blocking solution containing normal chicken serum (Biosera, 
Uckfield, UK) diluted 1:5 in TBS containing 5% (w/v) bovine serum albumin (BSA; Sigma-Aldrich Co. Ltd., UK). 
Sections were then incubated with primary antibody against the Leydig cell marker hydroxysteroid dehydroge-
nase 3-beta 1/6 (sc-30820, Lot #H0814; Santa Cruz Biotechnology, Germany) diluted 1:400 in blocking serum at 
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4 °C overnight. Next, sections were incubated with a biotin-conjugated secondary antibody (sc-2984; Santa Cruz 
Biotechnology, Germany), diluted 1:500 in blocking serum for 30 min at room temperature, followed by a 30 min 
incubation with streptavidin-horseradish peroxidase conjugate (SA-5004; Vector Labs, USA) diluted 1:1000 in 
TBS. Localisation of primary antibody was visualised by the addition of the chromogenic peroxidase substrate 
3,3′-diaminobenzidine (DAB; Vector Labs, Peterborough, UK) according to the manufacturer’s instructions. 
Sections were counterstained with haematoxylin, dehydrated and mounted with glass cover slips. Control sec-
tions (i) from which the primary antibody had been omitted, (ii) primary antibody was replaced with isotype IgG 
(I9140, Lot 047K6095; Sigma-Aldrich, Dorset, UK) and (iii) sections from Leydig cell ablated rat testes incubated 
with primary antibody were included (Supplemental Fig. 4). Images were captured using an Axio Scan Z.1 slide 
scanner (Carl Zeiss Ltd, Welwyn Garden City, UK).
Stereology. Leydig cells were identified in tissue sections by chromogenic immunostaining for HSD3B as 
described above. Leydig cell quantification was carried out using the stereology plug-in for Image-Pro plus 7.0 
software (Media Cybernetics, UK) and a Zeiss Axio Imager A1 microscope (Carl Zeiss, UK) with a Qimaging 
QICAM Fast 1394 digital camera (Qimaging, Canada) and a Prior ProScan automated stage (Prior Scientific 
Instrument Ltd, UK). In brief, the ‘count’ function was used to score nuclei of immuno-positive cells at 630X mag-
nification in a minimum of 70 random fields per section. Only fields containing ≥50% tissue area were scored. 
The resulting relative nuclear volume data were converted to absolute nuclear volume using testis weight. Mean 
nuclear volume was then measured from approximately 100 Leydig cell nuclei per section using the ‘nucleator’ 
function and used to calculate cell number per testis. This method has previously been shown to give comparable 
results to the dissector method for estimating cell number in the rat testis64.
Hormone analysis. Circulating luteinising hormone (LH) was measured in serum using an in-house ELISA 
as previously described65. Standard curves were prepared with 8 different concentrations (10, 5, 2.5, 1, 0.5, 0.25 
0.1 & 0 ng/mL). Samples, standards and controls were included in duplicate. Inter- and intra-assay CV were cal-
culated from two controls of low and high LH in duplicate. The inter-assay CV for low and high pools respectively 
were 10.8 and 12.6%. The intra-assay CV were 7.6 and 10.7%. The lower limit of detection was calculated at 0.1 ng/
mL. Testosterone was quantified in rat serum using an in house competitive ELISA. Briefly, 96-well plates (Greiner 
Bio-One GmbH, Germany) were coated with 100 µL of donkey anti rabbit IgG (Jackson ImmunoResearch Inc, 
USA) per well at a dilution of 1:500 in ELISA coating buffer (100 mM NaHCO3, pH 9.6). After overnight incuba-
tion at 4°C, plates were washed twice with wash buffer (0.05 M Tris-HCl, 0.05% Tween 20, pH 7.4) and incubated 
with 250 μL of blocking buffer (PBS pH 7.4 containing 0.5% BSA) for 1 hr at room temperature. Plates were then 
washed twice with wash buffer prior to the addition of standards, samples and controls (20 µL per well), followed 
by 80 µL of testosterone-HRP conjugate (Astra Biotech GmbH, Germany) at 1:20,000 in assay buffer (PBS pH 
7.4 containing 0.1% BSA and 250 ng/mL Cortisol), followed by 50 μL of rabbit anti-testosterone-19 antibody 
(AMS Biotechnology, USA) at 1:200,000 in assay buffer. Plates were incubated at room temperature for 2 hr on an 
IKA®, Schuttler MTS4 plate shaker (IKA Labortechnik, Germany), then washed 5 times with assay wash buffer. 
Next, 120 µL of substrate solution (3,3,5,5-Tetramethylbenzidine; Millipore Corporation, USA) was added to 
each well and plates were incubated at room temperature, without shaking, in the dark, for 20 mins. The reaction 
was stopped by the addition of 80 µL stop solution (2N H2SO4; Sigma-Aldrich, UK). Finally, plates were read on 
a plate reader at 450 nm. Standard curves were prepared from 8 different concentrations (24.3, 8.1, 2.7, 0.9, 0.3, 
0.1 0.03 & 0 ng/mL). Samples, standards and controls were included in duplicate. Inter- and intra-assay CV were 
calculated from two controls of low and high testosterone in duplicate. The inter-assay CV for low and high pools 
respectively were 13.6 and 7.2%. The intra-assay CV were 4.6 and 3.1%. The lower limit of detection was calcu-
lated at 0.2 ng/mL.
Genomic pcR. Genomic DNA was isolated from frozen testes using the GeneJET Genomic DNA Purification 
Kit (Thermo Scientific, UK) and interrogated for the presence/absence of human-specific genomic DNA by 
PCR as described by Caspi, et al.66. Multiplex PCR amplification of α-satellite region of human chromosome 
17 (HUMSAT17A) and rat beta actin (Actb; as an internal control) was performed using the Type-it Mutation 
Detect PCR Kit (QIAGEN Ltd., UK). The primer sequences were HUMSAT17A-FWD gggataatttcagctgactaaacag, 
HUMSAT17A-REV gtgtttcatagctgctctttcca and Actb-FWD tgtgttcttgccctctttgc, Actb-REV caggaaggaaggctggaaga. 
PCR products were analysed using the QIAxcel capillary electrophoresis system (QIAGEN Ltd., UK). Genomic 
DNA isolated directly from EM and DIM cultured Ad-PSCs was included as a positive control. A template nega-
tive control (water instead of gDNA) was included to ensure reagents were free of contaminating gDNA.
Quantitative Rt-pcR. Gene expression (mRNA) analyses were carried out as previously described67 
with minor modifications. In brief, total RNA was extracted from frozen testis tissues or from hAd-PSC cul-
tures using the RNeasy® Mini kit (QIAGEN Ltd., UK) following the manufacturer’s instructions with the inclu-
sion of an on column DNase (QIAGEN Ltd., UK) treatment step. For testis tissue, a Luciferase RNA (75 ng/
testis; Promega, UK) was added to each sample at the start of the extraction as an external control. RNA con-
centrations were estimated using a NanoDrop One spectrophotometer (Thermo Scientific, UK) with a 260:280 
absorbance ratio of ~2.0 indicative suitably pure RNA. cDNA was prepared from up to 2 μg total RNA using 
the SuperScript® VILO™ cDNA Synthesis Kit (Life Technologies, UK) following the manufacturer’s instruc-
tions and a reverse transcriptase negative (-RT) control was included to ensure reagents were free of nucleic 
acid contamination. Real-time PCR was carried using the ABI Prism 7900HT Real-Time PCR System (Applied 
Biosystems, UK) and the Roche Universal ProbeLibrary (Roche, UK) in 384-well format. Assays were designed 
using the online Universal Probe Library Assay Design Centre (Roche; https://lifescience.roche.com/en_gb/arti-
cles/Universal-ProbeLibrary-System-Assay-Design.html). Assays were designed spanning an intron to avoid the 
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amplification of potential genomic DNA contaminants. Additionally, an –RT and a template negative control 
(water instead of cDNA) were included for each assay to ensure reagents were free of contaminating nucleic 
acid. Details of each assay are listed in Table 1. The external Luciferase control was assayed using gcacatatcgag-
gtgaacatcac and gccaaccgaacggacattt forward and reverse primers respectively and, a 5′NED labelled probe 
(tacgcggaatacttc). Data were analysed using the ΔΔCt method, with the expression of each gene related to the 
external Luciferase control or internal ACTB control (Roche, UK) for rat testis and hAD-PSC cDNAs respectively. 
Amplification efficiency of qRT-PCR assays was first determined using a serial dilution of control cDNA. Assays 
with an efficiency between 90 and 105% were considered suitably efficient for ΔΔCt analyses.
Statistical analyses. Data are expressed as the mean ± S.E.M. Statistical analyses were carried out in 
GraphPad Prism 7.02 for Microsoft Windows (GraphPad Software Inc., USA). In the first instance, data distri-
bution was assessed using the Shapiro-Wilk normality test. Differences between two experimental groups were 
identified using an unpaired, two tailed, t-test. Differences between more than two experimental groups were 
identified using either a one-way analysis of variance (1-way ANOVA) or a Kruskal –Wallis test. In the case of 
1-way ANOVAs, Tukey’s post hoc analysis was used to compare means between groups. For Kruskal-Wallis, 
means were compared using Dunn’s post hoc test. A p-value of ≤0.05 was considered statistically significant.
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